This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

This study has been terminated.
(Strategic direction of the sponsor changed)
Information provided by (Responsible Party):
Nitric BioTherapeutics, Inc Identifier:
First received: October 16, 2007
Last updated: October 18, 2012
Last verified: October 2012
This study will test the safety and efficacy of nitric oxide gas in the treatment of venous leg ulcers

Condition Intervention Phase
Venous Ulcers Drug: Nitric Oxide - same dose 6 wks Drug: Nitric Oxide modified treatment Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Investigation of the Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Leg Ulcers of the Lower Extremities

Resource links provided by NLM:

Further study details as provided by Nitric BioTherapeutics, Inc:

Primary Outcome Measures:
  • Wound Healing [ Time Frame: Week 20 ]
    % Re-epithelialization

  • Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: up to 24 weeks ]
    All reported adverse events, related or unrelated to the study drug.

Enrollment: 4
Study Start Date: October 2007
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: A - Standard of Care (control)
Standard of care - dressings and sustained compression only
Experimental: B Same treatment for 6 weeks
200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
Drug: Nitric Oxide - same dose 6 wks
200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
Experimental: C - modified treatment, 5 wks lower dose
200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
Drug: Nitric Oxide modified treatment
200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound

Detailed Description:
Prospective, single center. Controlled study of a moisture retentive wound dressing and sustained compression with 6 weeks of 8 hour daily nitric oxide treatments.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have a venous stasis ulcer between the knee and the ankle.
  • Ulcer duration must be 60 days or greater

Exclusion Criteria:

  • Has an ulcer that is deemed by the Investigator to be caused primarily by a medical condition other than venous insufficiency
  • Suffers from diabetes mellitus with HbA1c ≥ 8%
  • Suffers from clinically significant arterial disease
  • Is pregnant, a nursing mother or a woman of child bearing potential who is not using an adequate form of contraception (or abstinent)

The above is a partial list of the inclusion and exclusion criteria; however, other inclusion and exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00545298

United States, Virginia
Retreat Hospital, Wound Healing Center
Richmond, Virginia, United States, 23220
Sponsors and Collaborators
Nitric BioTherapeutics, Inc
Principal Investigator: Joseph V Boykin, MD HCA Retreat Hospital
  More Information

Responsible Party: Nitric BioTherapeutics, Inc Identifier: NCT00545298     History of Changes
Other Study ID Numbers: CTP 1
Study First Received: October 16, 2007
Results First Received: August 8, 2012
Last Updated: October 18, 2012

Keywords provided by Nitric BioTherapeutics, Inc:
Nitric Oxide
Venous Leg Ulcers

Additional relevant MeSH terms:
Leg Ulcer
Varicose Ulcer
Postphlebitic Syndrome
Postthrombotic Syndrome
Pathologic Processes
Skin Ulcer
Skin Diseases
Varicose Veins
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Venous Insufficiency
Venous Thrombosis
Embolism and Thrombosis
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents processed this record on July 26, 2017